Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · IEX Real-Time Price · USD
2.855
+0.095 (3.44%)
At close: Apr 25, 2024, 3:59 PM
2.930
+0.075 (2.63%)
After-hours: Apr 25, 2024, 7:35 PM EDT
Aytu BioPharma Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Aytu BioPharma stock have an average target of 12.5, with a low estimate of 5.00 and a high estimate of 20. The average target predicts an increase of 337.83% from the current stock price of 2.86.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 9, 2023.
Analyst Ratings
The average analyst rating for Aytu BioPharma stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Initiates $5 | Strong Buy | Initiates | $5 | +75.13% | Aug 9, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +600.53% | May 31, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $220 → $120 | Strong Buy | Maintains | $220 → $120 | +4,103.15% | Jul 21, 2022 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $220 → $100 | Buy | Maintains | $220 → $100 | +3,402.63% | May 17, 2022 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $480 → $220 | Strong Buy | Maintains | $480 → $220 | +7,605.78% | Apr 28, 2022 |
Financial Forecast
Revenue This Year
85.22M
from 107.40M
Decreased by -20.65%
Revenue Next Year
78.63M
from 85.22M
Decreased by -7.73%
EPS This Year
-2.27
from -5.11
EPS Next Year
0.51
from -2.27
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 87.7M | 80.9M | 74.6M | 123.6M | 127.4M |
| Avg | 85.2M | 78.6M | 72.4M | 120.1M | 123.7M |
| Low | 81.9M | 75.5M | 69.6M | 115.4M | 118.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -18.3% | -5.0% | -5.2% | 70.6% | 6.1% |
| Avg | -20.7% | -7.7% | -7.9% | 65.7% | 3.1% |
| Low | -23.8% | -11.4% | -11.5% | 59.3% | -1.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -2.34 | 0.53 | 0.17 |
| Avg | -2.27 | 0.51 | 0.16 |
| Low | -2.19 | 0.49 | 0.16 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | -67.1% |
| Avg | - | - | -68.0% |
| Low | - | - | -69.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.